I thought it might be useful to give a report on my recent Tulsa-Pro treatment, since there appears to be little information about it on this forum.
I was diagnosed in June 2020 with Gleason score 4+3=7 adenocarcinoma from 3 positive cores out of 12 using a perennial biopsy. PSA was 11.5, having risen from 3.52 in 2017. Bone scan and multiparametric MRI showed no evidence of metastasis. MRI estimated a single lesion with approximate diameter 23mm in the anterior transitional zone. Clinical stage T2cN0M0 becasue tumour was located slightly to the left of the midline.
I had the TULSA procedure in September 2020 to ablate about 45% of my prostate. It was roughly a 3.5 hour general anaesthetic operation, followed by a two night hospital stay. I needed self-catheterisation (clean intermittent catheterisation) for about two months post-op. I had hormone therapy for six months using a combination of Delgalerix (abdominal injection) and bicalutamide (tablets).
Follow-up MRI checks over the subsequent three years were all non-suspicious. PSA values were 0.538 immediately post procedure, then a nadir of 0.02 in December 2020. Subsequent PSA: 0.529 May 2021, 0.576 January 2022, 0.678 April 2023, 0.663 October 2023.
Urine flow was improved by the procedure, and my sexual function was not degraded, apart from some reduction in semen volume. At this stage I am very satisfied with the treatment.
It was carried out at Hokuyu Hospital in Sapporo, since I spend a lot of time in Japan, and becasue there are no centres in the UK. The care there was excellent, and although BUPA do not cover TULSA, the cost was not too high at about GBP8,000 equivalent. Highly recommended!
Edited by member 24 Oct 2023 at 15:58
| Reason: Not specified